{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:46:07Z","timestamp":1787165167418,"version":"build-2736575974"},"reference-count":51,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T00:00:00Z","timestamp":1332806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Serologically active clinically quiescent (SACQ) systemic lupus erythematosus (SLE) patients' discordance presents a clinical dilemma. Does active serology alone warrant treatment? We explore outcomes in patients with and without a prolonged SACQ period, comparing the rate of damage accrual by Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index (SDI) and incidences of renal damage and coronary artery disease (CAD) over a decade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      SACQ was defined as a \u22652\u2010year sustained period without clinical activity, with persistent serologic activity (increased anti\u2013double\u2010stranded DNA and\/or hypocomplementemia). Antimalarials were permissible and corticosteroids\/immunosuppressives were not. The SACQ patients were matched for relevant variables with SLE controls. Change in the SDI and incidences of CAD and renal damage were compared. Descriptive statistics were used; comparisons were made using\n                      <jats:italic>t<\/jats:italic>\n                      \u2010tests and McNemar's tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty\u2010five SACQ patients and 110 controls were identified. The mean \u00b1 SD SDI score at 3 years from the start of the SACQ period was 0.70 \u00b1 1.27 in the SACQ patients versus 1.13 \u00b1 1.54 in controls (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001), and by 10 years was 1.26 \u00b1 1.68 versus 2.26 \u00b1 2.23 (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001); the intergroup difference in damage significantly increased over 10 years. Initially, 2 (3.6%) of the SACQ patients had CAD versus 7 (6.4%) of the controls (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.32), with 1 (1.8%) new case in SACQ patients versus 8 (7.3%) new cases in controls over 10 years (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.06). Baseline serum creatinine level did not differ between the groups. By definition, the SACQ patients had no baseline proteinuria versus 13 (12.3%) of the controls (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001). By year 10, 2 (3.6%) SACQ patients versus 26 (23.6%) controls had renal damage (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with a prolonged SACQ period accrued less damage over a decade compared to matched controls, supporting management with active surveillance without treatment during an SACQ period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.21568","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T13:12:50Z","timestamp":1323695570000},"page":"511-518","source":"Crossref","is-referenced-by-count":84,"title":["Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period"],"prefix":"10.1002","volume":"64","author":[{"given":"Amanda J.","family":"Steiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Iba\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray B.","family":"Urowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu485oa"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem112"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071297"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.126.4.607"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.41.4.388"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22198"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000224709.70133.f7"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90529-1"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120399680411335"},{"key":"e_1_2_6_14_2","first-page":"1570","article-title":"Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality","volume":"33","author":"Becker\u2010Merok A","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.08.004"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000099844.31524.05"},{"key":"e_1_2_6_18_2","first-page":"26","article-title":"Accelerated atherosclerosis in patients with systemic lupus erythematosus: a review of the causes and possible prevention","volume":"8","author":"Thomas GN","year":"2002","journal-title":"Hong Kong Med J"},{"key":"e_1_2_6_19_2","first-page":"824","article-title":"Disease activity over time (adjusted mean SLEDAI) predicts mortality and damage in SLE","volume":"32","author":"Ibanez D","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.10.953"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2005.01.008"},{"key":"e_1_2_6_22_2","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman DD","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.161.3843.806"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408368209085072"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100007"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306071665"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(76)90431-9"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.09.005"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.9.981"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203302lu158oa"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002126"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780220304"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.45.5.359"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/08916930400022616"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780190501"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10930"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh384"},{"key":"e_1_2_6_38_2","first-page":"2239","article-title":"Serologically active clinically quiescent systemic lupus erythematosus: predictors of clinical flares","volume":"21","author":"Walz LeBlanc BA","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90114-0"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330505"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2342::AID-ART397>3.0.CO;2-8"},{"key":"e_1_2_6_42_2","first-page":"824","article-title":"Adjusted mean Systemic Lupus Erythematosus Disease Activity Index\u20102K is a predictor of outcome in SLE","volume":"32","author":"Ibanez D","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg078"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2302oa"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu2028oa"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200104)31:4<1221::AID-IMMU1221>3.0.CO;2-P"},{"key":"e_1_2_6_47_2","first-page":"1785","article-title":"Anti\u2010dsDNA antibody testing by Farr and ELISA techniques is not equivalent","volume":"33","author":"Neogi T","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<76::AID-ANR10>3.0.CO;2-I"},{"key":"e_1_2_6_49_2","first-page":"1538","article-title":"Diagnostic value of anti\u2010nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti\u2010nucleosome with anti\u2010dsDNA antibodies","volume":"33","author":"Gutierrez\u2010Adrianzen OA","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.10.003"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1398.048"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22356"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.21568","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.21568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:22:24Z","timestamp":1759414944000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.21568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,27]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1002\/acr.21568"],"URL":"https:\/\/doi.org\/10.1002\/acr.21568","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,27]]}}}